Pipeline — registered trials by phase
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
— · Inflammation, Cataracts · Completed · est. 2014-10
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where ICON is lead sponsor; 1 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 6-K2026-10-08Report of foreign issuer
- 6-K2026-09-09Report of foreign issuer
- 6-K2026-08-20Report of foreign issuer
- 6-K2026-08-18Report of foreign issuer
- SCHEDULE 13G/A2026-08-13SCHEDULE 13G/A
- SCHEDULE 13G/A2026-08-06SCHEDULE 13G/A
- 6-K2026-08-06Report of foreign issuer
- 6-K2026-07-31Report of foreign issuer
- 6-K2026-07-30Report of foreign issuer
- 6-K2026-07-29Report of foreign issuer
- 6-K2026-07-22Report of foreign issuer
- 6-K2026-06-26Report of foreign issuer
- 6-K2026-06-23Report of foreign issuer
- 6-K2026-06-23Report of foreign issuer
- 6-K2026-06-17Report of foreign issuer
- 6-K2026-05-27Report of foreign issuer
- 6-K/A2026-05-276-K/A
- 20-F2026-05-27Annual report (foreign)
- 6-K2026-05-26Report of foreign issuer
- SCHEDULE 13G2026-05-15SCHEDULE 13G
- SCHEDULE 13G/A2026-05-15SCHEDULE 13G/A
- SCHEDULE 13G/A2026-05-15SCHEDULE 13G/A
- SCHEDULE 13G2026-05-06SCHEDULE 13G
- SCHEDULE 13G2026-05-06SCHEDULE 13G
- NT 20-F2026-05-01NT 20-F
- 6-K2026-04-29Report of foreign issuer
- SCHEDULE 13G/A2026-03-06SCHEDULE 13G/A
- SCHEDULE 13G/A2026-02-17SCHEDULE 13G/A
- 6-K2026-02-12Report of foreign issuer
- 6-K2026-01-07Report of foreign issuer
- SCHEDULE 13G2025-11-14SCHEDULE 13G
- SCHEDULE 13G2025-11-12SCHEDULE 13G
- 6-K2025-11-12Report of foreign issuer
- 6-K2025-10-23Report of foreign issuer
- 6-K2025-10-22Report of foreign issuer
- 6-K2025-09-24Report of foreign issuer
- 6-K2025-09-04Report of foreign issuer
- 6-K2025-09-04Report of foreign issuer
- 6-K2025-09-02Report of foreign issuer
- 6-K2025-08-26Report of foreign issuer
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.